Breakthrough Therapy Designations Market, By Application (Rare Disease, Oncology, Infectious Disease, Autoimmune Disease, Neurological Disorder, and Pulmonary Disease), By End-User (Clinic, Research Institute, Hospital, and Laboratories), and By Geography (EU, NA, APAC, LATAM, and MEA) Analysis, Size, Share, Trends, & Forecast from 2021-2027
REPORT HIGHLIGHT
The global breakthrough therapy designations market was valued at USD 68.4 billion by 2019, growing with 15.3% CAGR during the forecast period, 2021-2027.
Breakthrough therapy designation is a process that accelerates the development and review of drugs, which are intended to treat a serious condition such as cancer, and respiratory infections due to coronavirus. For instance, the BBC recently published a study conducted by Oxford University in cooperation with many hospitals in the UK along with the agreement of numerous patients and their families. The study involved dexamethasone as a part of “Recovery – Randomized Evaluation of COVID-19 Therapy”, to cure patients under clinical trials. This trial was set up in nine days and involved 11,500 COVID recruited patients in 175 hospitals across the UK.
According to the Food and Drug Administration, BT also offers indications in the preliminary clinical evidence demonstrating the significant improvement of drugs over available therapy on a clinically significant endpoint(s). The drug approval process, under BT designations, includes the drug review evaluation that is reviewed by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). On average, CDER receives approximately 100 requests per year, whereas CBER receives 15–30 requests per year.
Market Dynamics
Elevating count of drugs gaining BT status coupled with the rising demand for drugs curing rare diseases and cancer therapies are boosting the industrial growth. For instance, CDER Breakthrough Designation included a count of 156 approvals in 2019. Among these, the approval of Fam-Trastuzumab Deruxtecan-Nxki by Daiichi Sankyo is the latest. The global breakthrough therapy designation market dynamics are also affected directly due to the COVID pandemic, owing to the expedited approval process adopted in developed countries for the discovery of a cure for COVID patients. For instance, the European government-funded National Health Service (NHS) authorized to use steroid dexamethasone; as the world’s first coronavirus treatment in June 2020. The study proved effective in reducing the risk of death among severely ill patients.
Moreover, the increasing healthcare expenditure in emerging nations coupled with the improvement in Intellectual Property (IP) laws is also expected to propel the industrial growth during the forecast years. On the contrary, global breakthrough therapy designation market challenges include the expensive nature of breakdown therapy coupled with the diverging preference to generic medicines.
Application Takeaway
Based on the application, this industry is bifurcated into the rare disease, oncology, infectious disease, autoimmune disease, pulmonary disease, neurological disorder, and other diseases. Among these, the infectious disease segment is dominating the global breakthrough therapy designation market growth and is projected to continue at the same pace throughout the forecast years. This dominance is attributed to a surge in the count of anti-infective drugs gaining BT status all across the globe. As per Friends of Cancer Research, Exebacase, sponsored by ContraFect Corporation, was the latest agent that awaits FDA approval, after assigning a BT Designation Disclosure date of Feb. 24th, 2020. The agent treats infectious disease indicating the patients with MRSA bacteremia, including right-sided endocarditis.
Besides, the oncology and rare disease segment are also expected to have significant growth during the upcoming years, owing to the sudden outbreak of the COVID pandemic and the growing awareness about orphan drugs among the consumers. An article published by an online newsletter “ecancer”, in May 2020, stated that the people with cancer are highly mortal from COVID-19, as per the healthcare scientists of Montefiore Health System and Albert Einstein College of Medicine. However, the high cost of the drugs approved through BT designation serves to be the global breakthrough therapy designation market restraint, hampering the overall growth.
End-User Takeaway
By end-users, the industry is categorized into hospitals, clinics, research institutes, and laboratories. The research institute segment holds a significant share, followed by hospitals and laboratories. Global breakthrough therapy designation market size is expected to grow in the near future, owing to the shorter approval time for the latest innovative drugs and better product image. Also, the prevalence of chronic disease and the sudden outbreak of coronavirus are also responsible for fueling the growth of this industry.
Regional Takeaway
Regionally, the overall market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds the majority of share followed by Europe, owing to the shifting preference of patients and healthcare professionals for innovative medicines along with the better intellectual property laws in this region. Other factors such as the increasing disposable income, improving healthcare infrastructure, and the emergence of COVID-19 are supporting the market growth.
Moreover, the Asia Pacific and Latin American industry is expected to offer lucrative growth over the next few years. The development of favorable IP laws in emerging countries like India and China is responsible for positively affecting the overall growth. For instance, the updated data revealed by the World Intellectual Property Organization concluded a total growth rate of 43.66% and 62.66% for patents and trademarks respectively in India only. On the other hand, the growing demand for generic products is however likely to hamper the growth of the market.
COVID-19 Impact
The market is also impacted due to the COVID-19 outbreak. This has accelerated the demand for a drug that is effective in curing this deadly disease. The studies have also revealed that the development time through BT therapy is 30% to 50% less as compared to those without designation. This significant reduction in time consumed for the drug development process also plays an essential role in boosting the global breakthrough therapy designation market potential worldwide.
Key Vendor Takeaway
The leading players of the global breakthrough therapy designations market include Acadia, Amgen, Inc., Boehringer Ingelheim, AstraZeneca, AbbVie, Inc., Eli, Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Gilead, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Janssen Global Services, Pfizer, Pharmaceuticals, Inc., Sanofi, and Regeneron.
Due to the current pandemic condition worldwide, numerous companies are actively involved in new product development along with the innovation of a novel drug that is capable of curing COVID. Apart from this, numerous companies have received FDA approval under CDER Breakthrough Therapy to cure other conditions as well. Such developments account for the approval of IPILIMUMAB and NIVOLUMAB (established names) by Bristol-Myers Squibb Company in March 2020. IPILIMUMAB and NIVOLUMAB both in combination with Nivolumab can be used for the treatment of patients with hepatocellular carcinoma (HCC).
The market size and forecast for each segment and sub-segments has been considered as below:
- Historical Year – 2016 to 2018
- Base Year – 2019
- Estimated Year – 2020
- Projected Year – 2021 to 2027
TARGET AUDIENCE
- Traders, Distributors, and Suppliers
- Manufacturers
- Government and Regional Agencies
- Research Organizations
- Consultants
- Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BREAKTHROUGH THERAPY DESIGNATIONS MARKET KEY PLAYERS
- AbbVie, Inc.
- Acadia
- Amgen, Inc.
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
- Eli, Lilly and Company
- Hoffmann-La Roche Ltd
- Gilead Sciences
- GlaxoSmithKline plc
- Janssen Global Services
- Novartis AG
- Pfizer, Inc.
- Pharmaceuticals, Inc.
- Regeneron
- Sanofi S.A.
GLOBAL BREAKTHROUGH THERAPY DESIGNATIONS MARKET, BY APPLICATION
- Infectious Disease
- Rare Disease
- Neurological Disorder
- Oncology
- Other Disease
GLOBAL BREAKTHROUGH THERAPY DESIGNATIONS MARKET, BY END-USER
- Clinic
- Research Institute
- Hospital
- Laboratories
GLOBAL BREAKTHROUGH THERAPY DESIGNATIONS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Singapore
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Rest of MEA
TABLE OF CONTENT
1. BREAKTHROUGH THERAPY DESIGNATION MARKET OVERVIEW
1.1. Study Scope
2. EXECUTIVE SUMMARY
2.1. Market Snippet
2.1.1. Market Snippet by Application
2.1.2. Market Snippet by End-User
2.1.3. Market Snippet by Region
2.2. Competitive Insights
3. BREAKTHROUGH THERAPY DESIGNATION KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. BREAKTHROUGH THERAPY DESIGNATION INDUSTRY STUDY
4.1. Porter’s Five Forces Analysis
4.2. Marketing Strategy Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. BREAKTHROUGH THERAPY DESIGNATION MARKET: COVID-19 IMPACT ANALYSIS
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. BREAKTHROUGH THERAPY DESIGNATION MARKET LANDSCAPE
6.1. Market Share Analysis
6.2. Key Innovators
6.3. Breakdown Data, by Key manufacturer
6.3.1. Established Player Analysis
6.3.2. Emerging Player Analysis
7. BREAKTHROUGH THERAPY DESIGNATION MARKET – BY APPLICATION
7.1. Overview
7.1.1. Segment Share Analysis, By Application, 2020 & 2027 (%)
7.2. Oncology
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.3. Infectious Disease
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.4. Rare Disease
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.5. Autoimmune Disease
7.5.1. Overview
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.6. Pulmonary Disease
7.6.1. Overview
7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.7. Neurological Disorder
7.7.1. Overview
7.8. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.9. Other Disease
7.9.1. Overview
7.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8. BREAKTHROUGH THERAPY DESIGNATION MARKET – BY END-USER
8.1. Overview
8.1.1. Segment Share Analysis, By End-User, 2020 & 2027 (%)
8.2. Hospital
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.3. Clinic
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.4. Research Institute
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.5. Laboratories
8.5.1. Overview
8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9. BREAKTHROUGH THERAPY DESIGNATION MARKET– BY GEOGRAPHY
9.1. Introduction
9.1.1. Segment Share Analysis, By Region, 2020 & 2027 (%)
9.2. North America
9.2.1. Overview
9.2.2. Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
9.2.4. North America Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
9.2.5. North America Market Size and Forecast, By End-User, 2016 – 2027 (US$ Million)
9.2.6. The U.S.
9.2.6.1. Overview
9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.2.7. Canada
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
9.3.5. Europe Market Size and Forecast, By End-User, 2016 – 2027 (US$ Million)
9.3.6. Germany
9.3.6.1. Overview
9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.3.7. Italy
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.3.8. United Kingdom
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.3.9. France
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.3.10. Rest of Europe
9.3.10.1. Overview
9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Key Manufacturers in Asia Pacific
9.4.3. Asia Pacific Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
9.4.4. Asia Pacific Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
9.4.5. Asia Pacific Market Size and Forecast, By End-User, 2016 – 2027 (US$ Million)
9.4.6. India
9.4.6.1. Overview
9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.4.7. China
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.4.8. Japan
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.4.9. South Korea
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.4.10. Rest of APAC
9.4.10.1. Overview
9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.5. Latin America
9.5.1. Overview
9.5.2. Key Manufacturers in Latin America
9.5.3. Latin America Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
9.5.4. Latin America Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
9.5.5. Latin America Market Size and Forecast, By End-User, 2016 – 2027 (US$ Million)
9.5.6. Brazil
9.5.6.1. Overview
9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.5.7. Mexico
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.5.8. Argentina
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.5.9. Rest of LATAM
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.6. Middle East and Africa
9.6.1. Overview
9.6.2. Key Manufacturers in Middle East and Africa
9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
9.6.4. Middle East and Africa Market Size and Forecast, By Applications, 2016 – 2027 (US$ Million)
9.6.5. Middle East and Africa Market Size and Forecast, By End-User, 2016 – 2027 (US$ Million)
9.6.6. Saudi Arabia
9.6.6.1. Overview
9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.6.7. United Arab Emirates
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10. KEY VENDOR ANALYSIS
10.1. AbbVie, Inc.
10.1.1. Company Snapshot
10.1.2. Financial Performance
10.1.3. Types Benchmarking
10.1.4. Strategic Initiatives
10.2. Acadia
10.3. Amgen, Inc.
10.4. AstraZeneca
10.5. Boehringer Ingelheim
10.6. Bristol-Myers Squibb Company
10.7. Eli, Lilly and Company
10.8. F. Hoffmann-La Roche Ltd
10.9. Gilead
10.10. GlaxoSmithKline plc
10.11. Janssen Global Services
10.12. Novartis AG
10.13. Pfizer
10.14. Pharmaceuticals, Inc.
10.15. Regeneron
10.16. Sanofi
11. 360 DEGREE ANALYSTVIEW
12. APPENDIX
12.1. Assumption and Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
List of Tables
TABLE List of data sources
TABLE Market drivers; Impact Analysis
TABLE Market restraints; Impact Analysis
TABLE Breakthrough therapy designation market: Applications Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Applications
TABLE Global breakthrough therapy designation market, by Applications 2016 – 2027 (USD Million)
TABLE Breakthrough therapy designation market: End-User Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by End-User
TABLE Global breakthrough therapy designation market, by End-User 2016 – 2027 (USD Million)
TABLE Breakthrough therapy designation market: Regional snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Region
TABLE Global breakthrough therapy designation market, by Region 2016 – 2027 (USD Million)
TABLE North America breakthrough therapy designation market, by Country, 2016 – 2027 (USD Million)
TABLE North America breakthrough therapy designation market, by Applications, 2016 – 2027 (USD Million)
TABLE North America breakthrough therapy designation market, by End-User, 2016 – 2027 (USD Million)
TABLE Europe breakthrough therapy designation market, by Country, 2016 – 2027 (USD Million)
TABLE Europe breakthrough therapy designation market, by Applications, 2016 – 2027 (USD Million)
TABLE Europe breakthrough therapy designation market, by End-User, 2016 – 2027 (USD Million)
TABLE Asia Pacific breakthrough therapy designation market, by Country, 2016 – 2027 (USD Million)
TABLE Asia Pacific breakthrough therapy designation market, by Applications, 2016 – 2027 (USD Million)
TABLE Asia Pacific breakthrough therapy designation market, by End-User, 2016 – 2027 (USD Million)
TABLE Latin America breakthrough therapy designation market, by Country, 2016 – 2027 (USD Million)
TABLE Latin America breakthrough therapy designation market, by Application, 2016 – 2027 (USD Million)
TABLE Latin America breakthrough therapy designation market, by End-User, 2016 – 2027 (USD Million)
TABLE Middle East and Africa breakthrough therapy designation market, by Country, 2016 – 2027 (USD Million)
TABLE Middle East and Africa breakthrough therapy designation market, by Application, 2016 – 2027 (USD Million)
TABLE Middle East and Africa breakthrough therapy designation market, by End-User, 2016 – 2027 (USD Million)
List of Figures
FIGURE Breakthrough therapy designation market segmentation
FIGURE Market research methodology
FIGURE Value chain analysis
FIGURE Porter’s Five Forces Analysis
FIGURE Market Attractiveness Analysis
FIGURE COVID-19 Impact Analysis
FIGURE Pre & Post COVID-19 Impact Comparision Study
FIGURE Competitive Landscape; Key company market share analysis, 2019
FIGURE Application segment market share analysis, 2020 & 2027
FIGURE Application segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Oncology market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Infectious Disease market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Rare Disease market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Autoimmune Disease market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Pulmonary Disease market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Neurological Disorder market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Other Disease market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE End-User segment market share analysis, 2020 & 2027
FIGURE End-User segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Hospital market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Clinic market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Research Institute market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Laboratories market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Regional segment market share analysis, 2020 & 2027
FIGURE Regional segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE North America breakthrough therapy designation market share and leading players, 2019
FIGURE Europe breakthrough therapy designation market share and leading players, 2019
FIGURE Asia Pacific breakthrough therapy designation market share and leading players, 2019
FIGURE Latin America breakthrough therapy designation market share and leading players, 2019
FIGURE Middle East and Africa breakthrough therapy designation market share and leading players, 2019
FIGURE North America market share analysis by country, 2019
FIGURE U.S. breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Canada breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Europe breakthrough therapy designation market share analysis by country, 2019
FIGURE Germany breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Spain breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Italy breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE UK breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE France breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Rest of the Europe breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Asia Pacific breakthrough therapy designation market share analysis by country, 2019
FIGURE India breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE China breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Japan breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE South Korea breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Singapore breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Rest of APACbreakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Latin America breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Latin America breakthrough therapy designation market share analysis by country, 2019
FIGURE Brazil breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Mexico breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Argentina breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Rest of LATAM breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Middle East and Africa breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Middle East and Africa breakthrough therapy designation market share analysis by country, 2019
FIGURE Saudi Arabia breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE United Arab Emirates breakthrough therapy designation market size, forecast and trend analysis, 2016 to 2027 (USD Million)
